Endra Life Sciences Inc Reports Results For The Quarter Ended September 30: Earnings Summary

ENDRA Life Sciences

15/11/2024 15:53

* ENDRA Life Sciences Inc  NDRA.OQ  reported a quarterly
adjusted
loss of $9.54​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-700.00.  The lone analyst forecast for the
quarter was for a loss of $62.30 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * ENDRA Life Sciences Inc's reported EPS for the quarter was
a
loss of $9.54​.
    * The company reported a quarterly loss of $2.35 million.
    * ENDRA Life Sciences Inc shares had fallen by 24.8% this
quarter and lost 99.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 11% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ENDRA Life
Sciences Inc is 350.00 
This summary was machine generated from LSEG data November 15 at
03:53 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -62.30         -9.54          Beat
 Jun. 30 2024      -1.22 hundred  -1.40 hundred  Missed
 Mar. 31 2024                     -4.55 hundred  
 Dec. 31 2023                     -87.50